NCT00256269View on ClinicalTrials.gov

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

February 7, 2007

Study Completion Date

February 7, 2007

Conditions
Esophageal CancerGastroesophageal Cancer
Interventions
DRUG

Oxaliplatin

40 mg/m2 IV over 60 minutes Every 21 days

DRUG

Irinotecan

60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, Orange

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of California, Irvine

OTHER